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Background: Long-term changes in (bio)markers for cognitive frailty are not well
characterized. Therefore, our aim is to explore (bio)marker trajectories in adults who
became cognitively frail compared to age- and sex-matched controls who did not
become cognitively frail over a 15 year follow-up.We hypothesize that those who become
cognitively frail have more unfavorable trajectories of (bio)markers compared to controls.
Methods: The Doetinchem Cohort Study is a longitudinal population-based study that
started in 1987–1991 in men and women aged 20–59 years, with follow-up examinations
every 5 years. For the current analyses, we used data of 17 potentially relevant
(bio)markers (e.g., body mass index (BMI), urea) from rounds 2 to 5 (1993–2012). A global
cognitive functioning score (based on memory, speed, and flexibility) was calculated for
each round and transformed into education and examination round-adjusted z-scores.
The z-score that corresponded to the 10th percentile in round 5 (z-score = −0.77)
was applied as cut-off point for incident cognitive frailty in rounds 2–5. In total, 455
incident cognitively frail cases were identified retrospectively and were compared with
910 age- and sex-matched controls. Trajectories up to 15 years before and 10 years
after incident cognitive frailty were analyzed using generalized estimating equations
with stratification for sex and adjustment for age and, if appropriate, medication use.
Results were further adjusted for level of education, depressive symptoms, BMI, and
lifestyle factors.
Results: In men, (bio)marker trajectories did not differ as they ran parallel
and the difference in levels was not statistically significant between those who
became cognitively frail compared to controls. In women, total cholesterol trajectories
first increased and thereafter decreased in cognitively frail women and steadily
increased in controls, gamma-glutamyltransferase trajectories were more or less
stable in cognitively frail women and increased in controls, and urea trajectories
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increased in cognitively frail women and remained more or less stable in controls. Results
were similar after additional adjustment for potential confounders.
Conclusions: Out of the 17 (bio)markers included in this explorative study, differential
trajectories for three biomarkers were observed in women. We do not yet consider any
of the studied (bio)markers as promising biomarkers for cognitive frailty.
Keywords: cognitive frailty, markers, biomarkers, trajectories, Doetinchem Cohort Study
INTRODUCTION
Frailty is a state of increased vulnerability to adverse health
outcomes when exposed to stressors caused by the cumulative
decline in one or more domains of functioning, including the
cognitive domain (1–4). Moderate cognitive decline is part of
the normal aging process (5). Some elderly are confronted with
accelerated cognitive decline, which could eventually lead to
(mild) cognitive impairment or dementia. A (reversible) state
of cognitive vulnerability within mild cognitive impairment has
been termed “Cognitive frailty” (6). Although the existence
of cognitive frailty and its definition are still under debate
(7), there seems to be broad agreement that cognitively frail
people experience accelerated cognitive decline (i.e., cognitive
dysfunction) without having a form of dementia (8). In this study,
people were considered to be cognitively frail when their global
cognitive functioning was poor, given their level of education.
It is not yet fully understood how cognitive frailty develops
and whether it can be detected at an early stage. However,
there are indications that processes of inflammation and
oxidative stress are involved and that C-reactive protein (CRP)
could potentially serve as a biomarker (9). In addition, in
previous studies we observed associations between body mass
index (BMI), self-reported health, several biomarkers (e.g., β-
cryptoxanthin and zeaxanthin), and cognitive frailty (10, 11).
Unfavorable changes in these and other (bio)marker levels may
precede cognitive frailty. Studying these changes can provide
insight into the molecular pathways involved and could point out
promising biomarkers for cognitive frailty.
In the Doetinchem Cohort Study (DCS), various markers
(e.g., self-reported health, BMI) and biomarkers (e.g., CRP,
urea), have been measured over a time span of at least 15
years (12). Out of these (bio)markers, we identified 17 possibly
relevant (bio)markers for cognitive frailty. These are mainly
cardiometabolic, inflammatory, and oxidative stress markers.
These types of markers have been linked to cognitive decline
(13) and could therefore possibly serve as biomarkers for
cognitive frailty. Since cognitive frailty arises gradually, it is
meaningful to study how (bio)markers “behave” in the course
of developing cognitive frailty. These insights can be helpful
for the development of treatment and prevention. Therefore,
our aim is to explore the trajectories of several (bio)markers
during the development of cognitive frailty in adults and
compare these to the trajectories of age- and sex-matched
controls. We hypothesize that those who become cognitively frail




The DCS is a longitudinal population-based cohort study starting
in 1987–1991 (round 1) examining 7,769 men and women aged
20–59 years living in Doetinchem, a town in the Netherlands.
Adults who participated in the first round were invited for follow-
up examinations in 1993–1997 (round 2, n = 6,117, mean age:
46 years), 1998–2002 (round 3, n = 4,918, mean age: 51 years),
2003–2007 (round 4, n = 4,520, mean age: 56 years), and 2008–
2012 (round 5, n = 4,018, mean age: 60 years). Response rates
were 75% or higher in all rounds. Verschuren et al. (14) and
Picavet et al. (12) have described the study design in more detail.
All participants gave written informed consent in each round and
the study was approved by the Medical Ethics Committee of the
University Medical Center Utrecht.
Incident Cognitive Frailty
Cognitive functioning was assessed among participants aged≥45
years. Trained personnel carried out the cognitive tests according
to a standardized protocol. In rounds 2–5, global cognitive
functioning was measured with a neuropsychological test
battery assessing three domains: memory function, information
processing speed and cognitive flexibility. These were tested
using the 15 Words Verbal Learning Test (VLT) (immediate
and delayed recall) (15), the Stroop Color–Word Test (16), the
Word Fluency Test (17), and the Letter Digit Substitution Test
(18). Nooyens et al. (19) have described the cognitive tests in
more detail. From the separate test scores, one global cognitive
functioning score was calculated for each round. Next, the global
cognitive functioning scores were transformed into z-scores,
based on the mean and standard deviation in round 5, and
were adjusted for level of education and for the number of
tests performed during follow-up to take a possible learning
effect into account. The z-score that corresponded to the 10th
percentile in round 5 (z-score = −0.77) was applied as cut-off
point for incident cognitive frailty in rounds 2, 3, 4, and 5. This
is consistent with the definition used in one of our previous
studies, where we also defined people as being cognitively frail
when their global cognitive functioning was poor, given their
level of education (11). Since the prevalence of frailty naturally
increases with age, this was not included in the definition of
cognitive frailty. Participants with a score below the cut-off point
were considered incident cognitively frail and participants with
a score above this value were considered not cognitively frail. As
cognitive tests were only performed among participants aged≥45
years, we defined participants <45 years as not being cognitively
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Weight and height (to calculate the BMI), waist circumference,
and diastolic and systolic blood pressure were measured
according to standard protocols (14). Standardized
questionnaires were used to obtain data on self-reported
health, depressive symptoms (assessed with the Mental Health
Inventory-5 and the Vitality dimension of the 36-Item Short-
Form Health Survey) (20, 21), level of education, smoking
status, alcohol consumption, physical activity (categorized
using the Cambridge Physical Activity Index) (22), use of
anti-hypertensive medication, cholesterol-lowering medication,
and glucose-lowering medication.
Biomarkers
Total and high-density lipoprotein (HDL) cholesterol were
measured with standardized enzymatic methods. In 2013–2014,
standardized enzymatic methods were used to retrospectively
determine triglycerides, alanine aminotransferase (ALT),
gamma-glutamyltransferase (GGT), high sensitivity CRP,
albumin, uric acid, cystatin C, and creatinine of rounds 2–5
using blood plasma that had been stored in freezers. Participants
with only one measurement of the (bio)markers were excluded
and participants who were pregnant in a particular round were
excluded for that round only. Details of all measurements are
described in the Appendix A (Supplementary Material).
Statistical Analyses
Matching
The time of incident cognitive frailty was the first examination
round in which participants scored below the cut-off point of
−0.77. From this point in time, we were able to investigate
trajectories with a maximum of 15 years before and 10 years after
incident cognitive frailty. There were not enough observations
to study the trajectories up to 15 years after incident cognitive
frailty. Both cognitive frailty and biomarker levels vary strongly
by sex and age. Therefore, we used a matching design in
which each incident cognitively frail person was matched to
two controls based on sex, age (with 5-year age categories), and
examination round. We excluded two incident cognitively frail
cases, as no suitable controls could be identified.
(Bio)marker Trajectories
Trajectories of (bio)markers for incident cognitively frail
cases and controls were analyzed using generalized estimating
equations (GEE) with an unstructured correlation structure. The
GEE analysis was performed for each (bio)marker (dependent
variable) separately and with cognitive frailty (“yes” vs. “no”) as
the main determinant. This resulted in separate estimates (i.e.,
adjusted marginal means) at each point in time for cases and
controls.With these estimates, trajectories for the cognitively frail
and the controls were constructed. This approach is consistent
with the method used by Hulsegge et al. (23).
Analyses were stratified for sex and the model included age
(linear and quadratic), examination round (categorical variable
with round 5 as reference category), and time (categorical
variable). Time consisted of six categories ranging from T−15
to T+10 with T0 as the moment of incident cognitive frailty.
Age was centered at 60 years because this was approximately
the mean age at round 5, which resulted in (bio)marker levels
of someone who was hypothetically 60 years old. Trajectories
of systolic and diastolic blood pressure were adjusted for
self-reported anti-hypertensive medication, trajectories of total
cholesterol, HDL cholesterol and triglycerides were adjusted for
self-reported cholesterol-lowering medication, and trajectories
of glucose were adjusted for the self-reported use of glucose-
lowering medication.
Triglycerides, ALT, GGT, and CRP had a skewed distribution.
Therefore, we log-transformed these biomarkers and reported
back-transformed geometric means. Differences between
trajectories of cognitively frail people and their controls were
tested using an overall interaction term between cognitive
frailty and time, and a p-value lower than 0.1 was considered
statistically significant. This was obtained via the joint tests
for GEE, where differences in slopes were calculated based on




∗T+10) with T0 (i.e., moment of incident
cognitive frailty) as reference category.
To summarize, trajectories up to 15 years before and 10 years
after incident cognitive frailty were analyzed and compared to
controls using GEE with stratification for sex and adjustment for
age and, if appropriate, medication use (model 1). We verified
whether the results changed after additional adjustment for level
of education, depressive symptoms (model 2), BMI, smoking,
alcohol intake, and physical activity (model 3). Trajectories of
BMI and waist circumference were not adjusted for BMI.
We performed a sensitivity analysis to study the potential
impact of loss to follow-up due to mortality on our results. To
this end, we excluded participants who died during the follow-
up period (1993–2012) along with their matched case and/or
control(s) and compared the results to those obtained in the total
population. All analyses were performed using SAS 9.4 software
(SAS Institute, Cary, North Caroline, USA).
RESULTS
Population Characteristics
After excluding participants≥45 years without data on cognitive
functioning and applying the additional exclusion criteria, 5,139
participants remained for further analyses. Over the course of the
study, 6 participants were defined as incident cognitively frail in
round 2, 116 participants in round 3, 134 participants in round
4, and 202 participants in round 5. In total, 455 participants
became cognitively frail of which 303 (67%) were men and 152
(33%) were women. At incident cognitive frailty (T0), men had
an average age of 65.5 (SD 7.6) and women of 66.9 (SD 7.8).
Cognitively frail people more often had a low level of education
and a slightly higher BMI, waist circumference, and systolic blood
pressure than controls (Table 1). In addition, cognitively frail
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Age (years), mean (SD) 63.0 (7.8) 65.5 (7.6) 64.6 (8.0) 66.9 (7.8)
Low level of education, % 42 49 62 70
LIFE-STYLE FACTORS
Current smoker, % 15 24 17 14
Alcohol consumption (1 or more glasses/week), % 77 76 60 39
MEDICATION USE
Anti-hypertensive, % 24 27 29 34
Cholesterol-lowering, % 17 22 16 20
Glucose-lowering, % 6 10 6 7
HEALTH
Poor or fair self-reported health, % 16 23 22 34
Mental health (range 0–100), mean (SD) 81.3 (14.3) 78.2 (15.9) 75.6 (15.4) 70.2 (17.3)
Vitality (range 0–100), mean (SD) 71.0 (17.4) 68.9 (18.0) 65.8 (17.4) 59.9 (19.8)
ANTHROPOMETRIC DATA
BMI (kg/m2), mean (SD) 26.9 (3.5) 27.4 (3.7) 27.1 (4.7) 28.3 (5.5)
Waist circumference (cm), mean (SD) 100.7 (10.0) 102.7 (10.5) 93.5 (12.0) 97.4 (13.3)
Systolic blood pressure (mmHg), mean (SD) 134.7 (17.2) 138.0 (18.6) 133.8 (18.5) 137.8 (19.4)
Diastolic blood pressure (mmHg), mean (SD) 81.9 (9.8) 81.4 (9.9) 79.9 (9.7) 80.4 (10.1)
BIOMARKERS
Total cholesterol (mmol/L), median (IQR) 5.5 (4.8–6.1) 5.3 (4.4–6.3) 5.9 (5.1–6.7) 5.9 (5.4–6.5)
HDL cholesterol (mmol/L), median (IQR) 1.21 (1.00–1.44) 1.17 (0.98–1.42) 1.51 (1.23–1.81) 1.39 (1.17–1.67)
Glucose (mmol/L), median (IQR) 5.3 (4.8–6.1) 5.4 (4.9–6.1) 5.2 (4.8–5.8) 5.3 (4.9–5.9)
Triglycerides (mmol/L), median (IQR) 1.45 (1.06–2.07) 1.55 (1.10–2.08) 1.40 (1.05–1.90) 1.54 (1.11–2.10)
ALT (U/L), median (IQR) 18 (14–24) 18 (14–24) 16 (12–20) 14 (11–18)
GGT (U/L), median (IQR) 28 (19–40) 27 (20–41) 19 (15–29) 19 (14–26)
CRP (mg/L), median (IQR) 1.17 (0.62–2.40) 1.61 (0.81–3.07) 1.38 (0.68–2.89) 1.50 (0.70–2.48)
Albumin (g/L), median (IQR) 45 (43–46) 45 (43–46) 45 (43–47) 45 (43–46)
Cystatin C (mg/L), median (IQR) 0.86 (0.78–0.97) 0.91 (0.81–1.02) 0.81 (0.72–0.94) 0.89 (0.79–0.99)
Creatinine (umol/L), median (IQR) 84 (76–93) 83 (76–91) 67 (60–74) 69 (62–77)
Uric acid (mmol/L), median (IQR) 0.34 (0.29–0.38) 0.33 (0.29–0.38) 0.27 (0.23–0.30) 0.27 (0.22–0.32)
Urea (mmol/L), median (IQR) 6.2 (5.4–7.1) 6.2 (5.3–7.4) 5.8 (4.9–6.6) 6.1 (5.1–7.2)
BMI, body mass index; HDL cholesterol, high-density lipoprotein cholesterol; ALT, alanine aminotransferase; GGT, gamma glutamyltransferase; CRP, C-reactive protein.
men and women more often reported to have poor or fair health
and their medication use was higher compared to controls.
(Bio)marker Trajectories
In our main model (i.e., model 1), we observed no differences
in (bio)marker trajectories between incident cognitively frail
men and controls as the trajectories ran parallel and the
difference in levels was not statistically significant. In women,
we observed differences in the shape of the trajectories of total
cholesterol (p = 0.067), GGT (p = 0.008), and urea (p = 0.002)
between incident cognitively frail women and controls (Figure 1
and Appendix B Table 1 in Supplementary Material). Total
cholesterol increased before women became cognitively frail and
decreased after incident cognitive frailty (T0), while in controls,
total cholesterol levels steadily increased over time. GGT was
more or less stable in incident cognitively frail women, while in
controls, GGT levels slowly increased from T−10 onwards. Urea
increased over time in incident cognitively frail women, while in
controls, urea levels remained more or less stable.
After further adjustment for level of education and depressive
symptoms (model 2), we found no differences in (bio)marker
trajectories for men. In women, we found differences in the
same biomarker trajectories as in model 1 (i.e., total cholesterol,
GGT, urea) and additionally observed a difference in trajectories
for ALT in women (p = 0.046) (Appendix B Table 1 in
Supplementary Material). When further adjusting for BMI and
life-style factors (model 3), we still observed no differences in
(bio)marker trajectories for men. In women, differences in the
trajectories for GGT, urea, and ALT between incident cognitively
frail women and controls remained, but the difference in total
cholesterol trajectory (p = 0.109) was just above our threshold
(p-value for interaction <0.1).
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FIGURE 1 | Trajectories of (bio)markers for incident cognitively frail men and women and their controls. Trajectories of self-reported health (A), body mass index (B),
waist circumference (C), diastolic blood pressure (D), systolic blood pressure (E), total cholesterol (F), HDL cholesterol (G), glucose (H), triglycerides (I), ALT (J), GGT
(K), CRP (L), albumin (M), cystatin C (N), creatinine (O), uric acid (P), and urea (Q) of incident cognitively frail people (red lines) and controls (green lines) with 95%
confidence intervals stratified by sex and corrected for age and, if appropriate, medication use (model 1), where men and women were hypothetically 60 years old at
the time of incident cognitive frailty. A difference (p-value for interaction <0.1) in (bio)marker trajectory between those with and without incident cognitive frailty are
indicated by an asterisk. HDL cholesterol, high-density lipoprotein cholesterol; ALT, alanine aminotransferase; GGT, gamma glutamyltransferase; CRP, C-reactive
protein. Geometric means are shown for triglycerides, ALT, GGT, and CRP.
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To explore the potential impact of loss to follow-up due to
mortality on our results, we performed a sensitivity analysis
using model 1 in which we excluded participants who died
(n = 130) during the follow-up period (1993–2012). In men, 61
cognitively frail and 40 controls died. In women, 16 cognitively
frail and 13 controls died. Excluding these participants, along
with their matched case and/or control(s), resulted in the
exclusion of 333 participants in total. After exclusion, in men, the
trajectories of total cholesterol (p = 0.061) and BMI (p = 0.082)
differed between cognitively frail men and controls. In women,
consistent with the observed differences in the total population,
the trajectories of total cholesterol (p= 0.066), GGT (p= 0.018),
and urea (p = 0.001) differed between cognitively frail women
and controls. In addition, the trajectories of ALT (p = 0.057),
and albumin (p = 0.057) also became different between
cognitively frail women and controls (Appendix B Figure 1 in
Supplementary Material).
DISCUSSION
Our aim was to examine whether (bio)marker trajectories differ
for those who become cognitively frail compared to those who
do not over a follow-up of 15 years. In addition, we hypothesized
more unfavorable trajectories for those who became cognitively
frail compared to controls. In our main model (model 1),
we observed no differences in (bio)marker trajectories between
incident cognitively frail men and controls as the trajectories
ran parallel and the difference in levels was not statistically
significant. In women, we observed differences in the shape of the
trajectories of total cholesterol, GGT, and urea between incident
cognitively frail women and controls.
Against our expectations, most of the 17 (bio)markers
included in this study did not show deviating trajectories
between those who became cognitively frail and those who did
not. This was, for example, surprising for the inflammation
marker CRP, since this biomarker has, longitudinally, been
linked to physical frailty (24), cognitive decline (25), and risk
of dementia (26, 27), and therefore could serve as a biomarker
for cognitive frailty. However, also other epidemiological studies
report inconsistent findings regarding longitudinal measures of
inflammationmarkers and cognitive decline (28, 29). In addition,
Soysal et al. (30) showed that higher CRP and interleukin-6
(IL-6) levels are cross-sectionally associated to physical frailty,
but not longitudinally. Although this study focused on physical
frailty, it seems consistent with our null findings regarding
cognitive frailty.
We did find a difference in the trajectory for total cholesterol
in women. Total cholesterol increased before women became
cognitively frail and decreased after incident cognitive frailty
(T0), while in controls, total cholesterol levels steadily increased
over time. In a previous cross-sectional study in MARK-AGE,
we also found lower cholesterol levels among people who were
already cognitively frail compared to people without frailty (10).
Solomon et al. (31) found that non-demented people with high
total cholesterol levels around age 50 had poorer cognition 20
years later. In addition, their total cholesterol levels decreased
after age 50. The pattern Solomon et al. (31) describe seems
comparable to the trajectory we found in incident cognitively frail
women. The decline we observed in total cholesterol levels after
becoming cognitively frail could be caused by various factors, one
of which is medication use. The analyses were adjusted for self-
reported use of cholesterol-loweringmedication, but information
about medication type, dose and therapy compliance were not
collected and could therefore not be included in these analyses.
Hence, it is unclear whether the trajectories differ due to the
occurrence of cognitive frailty, or whether other effects, like a
treatment effect, is underlying this difference.
We also observed different urea and GGT trajectories in
incident cognitively frail women compared to controls. Higher
urea levels can be caused by disrupted blood flow through the
kidneys for example through heart failure (32). In contrast, we
found lower GGT levels in incident cognitively frail women,
while heart failure would also cause increased, and not decreased,
GGT levels (33). Lower GGT levels could be caused, for example,
by the use of clofibrate, a lipid-lowering agent controlling high
cholesterol and triglyceride levels. When adjusting for the use
of cholesterol-lowering medication for GGT, results remained
similar. It is suggested that serum GGT within the normal range
is an early marker for oxidative stress (34). Oxidative stress has
been suggested to be associated with frailty (35) and increased
GGT levels in later life (80 years and older) were associated
with cognitive decline (36). However, we unexpectedly observed
lower instead of higher GGT levels in cognitively frail women
compared to controls, indicating that cognitive frail women
might have less oxidative stress. Overall, there does not seem to
be a reasonable explanation for the course of these trajectories.
We cannot exclude the possibility that the trajectories of GGT
and urea are chance findings.
Differences in (bio)marker trajectories were observed among
women, but not among men. We found that more men had poor
cognitive functioning compared to women (i.e., more men were
identified as incident cognitively frail than women). On the other
hand, differences in cognitive functioning between the incident
cognitively frail men and their controls were smaller compared
to the differences observed in women. Possibly, the women who
we identified as incident cognitively frail were relatively worse
off than the incident cognitively frail men, having relatively
poorer cognitive function and potentially poorer overall health
and therefore we only found differences between trajectories
for women.
We studied the potential impact of loss to follow-up due to
mortality on our results. This was appropriate since some of
the trajectories for women indicated a (rapidly) deteriorating
health. For example, decreasing cholesterol levels could be caused
by malnutrition and increasing urea levels could be caused by
heart failure. As expected, mortality rate was higher among
those who became cognitively frail compared to those who did
not. However, excluding these participants did not materially
change the results. In fact, the differences in trajectories for total
cholesterol, GGT, and urea in women remained the same and
seemed therefore rather robust.
We considered people as being cognitively frail when their
global cognitive functioning was poor, given their level of
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education. Since the prevalence of frailty naturally increases with
age, this was not included in the definition of cognitive frailty.
The most important difference between our operationalization
of cognitive frailty and the classic operationalization for mild
cognitive impairment (MCI) (37) is that our definition of
cognitive frailty did not include subjective memory complaints.
Also, we did not include self-reported activities of daily living
which is part of the MCI definition. Recently, a definition for
cognitive frailty was proposed combining physical frailty with
MCI (38). Since we have previously observed that it is possible
to be cognitively frail without being physically frail (10), we
defined cognitive frailty only based on cognitive functioning. In
our manuscript, the term “cognitive frailty” represents cognitive
dysfunction, independent of other (physical) limitations and is
only based on poor cognitive functioning given the level of
education. We explicitly adjusted for level of education, since
highly educated people can also experience cognitive dysfunction
and this would otherwise be masked by their cognitive reserves.
One of the strengths of this study is that both cognitive
functioning, using a comprehensive neuropsychological test
battery, and multiple (bio)markers were objectively measured
in four rounds over a follow-up of 15 years, making this a
unique cohort for studying the relation between (bio)markers
and cognitive functioning over time. In addition, all biomarkers
of rounds 2–5 were measured in a single run, limiting inter-
assay variation.
This study has some limitations. We tried to include all
relevant confounders in the analyses (model 3) but residual
confounding may still be present. However, adjustment for
confounders had a marginal effect in the results. Further,
cognitive functioning was not assessed in participants younger
than 45 years. We defined these participants as not being
cognitively frail under the assumption that people become
cognitively frail with advancing age, mostly from 60 years
onwards. In addition, since this population was still relatively
young, it could have been too young to find (bio)markers
for cognitive frailty. Moreover, since cognitive frailty can be
described as a complex syndrome, multiple factors can influence
the development of this syndrome. This makes it challenging
to identify biomarkers for cognitive frailty. Further, we were
unable to exclude participants with dementia. However, given the
age-distribution of the cohort, the prevalence and incidence of
dementia would be quite low and is therefore unlikely to have
influenced our results. Finally, due to the age- and sex-matched
study design, the power was limited to analyze differences at
any time point. However, more power would probably not lead
to other differences in trajectories, because most trajectories
run almost parallel and that aspect is unlikely to change with
more power.
In conclusion, out of the 17 (bio)markers included in this
explorative study, different trajectories between incident
cognitively frail women and their controls were found
for three biomarkers. However, the relation between these
biomarkers and the development of cognitive frailty is unclear.
Future studies are needed to confirm these findings. Given
the results of this study, we do not yet consider any of
the studied (bio)markers as promising (bio)markers for
cognitive frailty.
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